BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Xie C, Cao K, Peng D, Qin L. RPLP1 is highly expressed in hepatocellular carcinoma tissues and promotes proliferation, invasion and migration of human hepatocellular carcinoma Hep3b cells. Exp Ther Med 2021;22:752. [PMID: 34035849 DOI: 10.3892/etm.2021.10184] [Reference Citation Analysis]
2 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Berlow NE. Probabilistic Boolean Modeling of Pre-clinical Tumor Models for Biomarker Identification in Cancer Drug Development. Curr Protoc 2021;1:e269. [PMID: 34661991 DOI: 10.1002/cpz1.269] [Reference Citation Analysis]
4 Cao L, Han Y, Pei L, Yue Z, Liu B, Cui J, Jia M, Wang H. A Serum Metabolite Classifier for the Early Detection of Type 2 Diabetes Mellitus-Positive Hepatocellular Cancer. Metabolites 2022;12:610. [DOI: 10.3390/metabo12070610] [Reference Citation Analysis]
5 Zamora-León SP. Hepatocellular carcinoma biomarkers, an imminent need. World J Gastrointest Oncol 2021; 13(11): 1847-1849 [PMID: 34853655 DOI: 10.4251/wjgo.v13.i11.1847] [Reference Citation Analysis]
6 Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
7 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Jia J, Ga L, Liu Y, Yang Z, Wang Y, Guo X, Ma R, Liu R, Li T, Tang Z, Wang J. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Front Immunol 2022;13:923031. [DOI: 10.3389/fimmu.2022.923031] [Reference Citation Analysis]
9 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Xiang L, Chen LM, Zhai YJ, Sun WJ, Yang JR, Fan YC, Wang K. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma. Life Sci 2021;270:119061. [PMID: 33454364 DOI: 10.1016/j.lfs.2021.119061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]